West Pharmaceutical Services Renews 10-Year Technology Crosslicense and Distributorship Agreements with Daikyo Seiko

West Pharmaceutical Services and Daikyo Seiko Formalize Renewed Long-Term Partnership

West Pharmaceutical Services, Inc., headquartered in Exton, Pennsylvania, disclosed on July 14, 2026 that it has entered into a renewed set of commercial and technology agreements with Daikyo Seiko, Ltd., a Japan-based manufacturer in which West maintains a 49% ownership interest. The three agreements — collectively referred to in the disclosure as "the Agreements" — consist of one Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements. All three became effective on July 14, 2026.

The announcement highlights the depth of the existing commercial relationship between West and Daikyo, a partnership that has been governed by formal agreements since at least January 2017. The new agreements replace and update the prior framework, which had also been amended by a Letter Agreement dated July 2, 2018, and an Amendment Agreement dated October 15, 2019. The current iteration is described in the disclosure as substantially similar in terms to those prior agreements, reflecting continuity rather than a fundamental restructuring of the relationship.

Technology Crosslicense Agreement: Scope of Know-How and Patent Sharing

The Crosslicense Agreement provides that both West Pharmaceutical Services and Daikyo Seiko will share their respective know-how with each other and cooperate in the joint development of a broad range of pharmaceutical packaging and drug delivery products. The filing specifies that the covered product categories include closures, vials, cartridges, syringes, medical device components, and similar products used in the packaging, delivery, administration, or dispensing of pharmaceutical products — a core part of West's global business.

Each party is permitted to license the other's know-how, patents, and trademarks in connection with the manufacture, use, and sale of those products. The disclosure states that Daikyo's license from West is non-exclusive, while West's license from Daikyo is exclusive outside of Japan, subject to certain limited exceptions. The Crosslicense Agreement is described as royalty-free, except for a fixed royalty rate that is generally applicable to the licensing of certain patents and non-patented technical information. The company did not disclose the specific royalty rate in the filing.

Distributorship Rights: West as Exclusive International Distributor of Daikyo Products

One of the two Distributorship Agreements grants West Pharmaceutical Services the role of exclusive distributor of Daikyo products in all countries other than Japan, subject to certain limited exceptions. This arrangement gives West significant commercial reach for Daikyo's product portfolio across international pharmaceutical markets, leveraging West's established global distribution infrastructure.

The second Distributorship Agreement moves in the opposite direction, authorizing Daikyo to act as a non-exclusive distributor of West's products within Japan. The disclosure notes that both Distributorship Agreements are otherwise substantially similar in their material terms and conditions, suggesting a balanced and reciprocal framework designed to serve each party's home and international markets. The company did not disclose specific revenue figures or volume commitments associated with either Distributorship Agreement in the filing.

Ten-Year Term and Conditions Under Which Agreements May Be Terminated

Each of the three Agreements carries a 10-year term, beginning July 14, 2026. This long-dated structure provides a degree of commercial certainty for both West and Daikyo over the coming decade and signals the strategic importance each party places on the relationship. The 10-year term aligns with the duration typical of complex technology licensing and distribution partnerships in the pharmaceutical packaging sector.

The filing also outlines circumstances under which any of the Agreements may be terminated before the end of their respective terms. These include, but are not limited to, mutual written consent of both parties or a change in control of either party. Investors may note that the change-of-control termination provision introduces a structural consideration for any potential future corporate transaction involving either West or Daikyo. If the Crosslicense Agreement is terminated, the disclosure states that the parties have agreed to negotiate within a specified period the terms under which they may continue to use the know-how and trademarks and to make, use, or sell products under licensed patents.

West's 49% Ownership Interest in Daikyo and Its Strategic Significance

West Pharmaceutical Services holds a 49% ownership stake in Daikyo Seiko, Ltd., making Daikyo a significant equity-method investment for the company. This ownership position means the two firms are not purely arm's-length commercial partners — they share financial interests as well as technology and distribution arrangements. The combination of a substantial equity stake and comprehensive licensing and distribution agreements underscores the integrated nature of the West-Daikyo relationship within West's broader global business model.

The renewed Agreements reinforce that West's international commercial strategy depends meaningfully on its partnership with Daikyo, particularly for the distribution of Daikyo-manufactured pharmaceutical packaging components in markets outside Japan. The reciprocal nature of the arrangements — with West distributing Daikyo's products globally and Daikyo distributing West's products in Japan — reflects a complementary geographic and operational fit between the two companies. The company did not provide financial projections or revenue impact estimates related to these agreements in the filing.

Products Covered: Pharmaceutical Packaging and Drug Delivery Components

The Agreements cover a well-defined set of product categories central to pharmaceutical supply chains. These include closures, vials, cartridges, syringes, medical device components, and similar products that are used in connection with the packaging, delivery, administration, or dispensing of pharmaceutical products. These component categories are integral to the drug manufacturing and distribution process and represent core markets for West Pharmaceutical Services.

The breadth of product coverage under the Crosslicense Agreement — spanning both patented and non-patented technical information as well as trademarks — reflects the comprehensive technological collaboration between the two companies. By jointly developing and sharing know-how across this range of products, both parties gain access to a wider technology base than either might develop independently. Investors may view this as supportive of West's competitive positioning in the global pharmaceutical packaging and drug delivery components market.

Royalty Structure and Financial Terms Disclosed in the Filing

The Crosslicense Agreement is described as royalty-free as a general matter, with one important qualification: a fixed royalty rate applies to the licensing of certain patents and non-patented technical information. The filing does not elaborate on which specific patents or technical information categories are subject to this fixed royalty, nor does it disclose the rate itself. Investors seeking a full understanding of the financial mechanics of the arrangement will need to await the filing of the redacted agreement exhibits.

The company disclosed that redacted copies of each of the Agreements will be filed as exhibits to the company's Quarterly Report for the quarter ending September 30, 2026. This means the complete text of the agreements, subject to any redactions approved by applicable regulatory procedures, will become available as part of that subsequent periodic report. The company did not disclose any upfront payments, minimum purchase obligations, or aggregate financial commitments associated with the Agreements in the current filing.

Comparison with Prior Agreements: Continuity of Commercial Framework

The disclosure emphasizes that the terms of the new Agreements are substantially similar to the terms of the prior arrangements — the Amended and Restated Technology Exchange and Crosslicense Agreement dated January 18, 2017, and the two Distributorship Agreements also dated January 18, 2017, as subsequently modified by the Letter Agreement of July 2, 2018 and the Amendment Agreement of October 15, 2019. This characterization suggests that the renewal is designed to preserve the established framework rather than to introduce significant structural changes to the relationship.

For investors, the continuity of the agreement terms means the operational and financial dynamics of the West-Daikyo partnership are broadly expected to remain consistent with the approach that has governed the relationship over the past several years. The update and renewal of these agreements may itself be interpreted as a signal of ongoing satisfaction with the existing framework by both parties, though the company made no such characterization in the filing. The immediate share price impact was not clear from available public information.

Authorization and Execution of the Agreements on July 14, 2026

The disclosure was authorized and signed on behalf of West Pharmaceutical Services by Norman D. Finch Jr., Senior Vice President, General Counsel and Corporate Secretary, as of July 14, 2026 — the same date the Agreements became effective. This simultaneous execution and reporting reflects the material nature of the Agreements, which triggered disclosure obligations as a material definitive agreement entered into by the company.

West Pharmaceutical Services is a Pennsylvania-incorporated company with its principal executive offices located at 530 Herman O. West Drive, Exton, Pennsylvania. The company's common stock carries a par value of $0.25 per share and is listed on the New York Stock Exchange. The company did not disclose any further details regarding internal approvals or board-level authorizations related to the execution of the Agreements beyond the information contained in the disclosure.